BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 22423483)

  • 1. Apigenin inhibits cell migration through MAPK pathways in human bladder smooth muscle cells.
    Liu Q; Chen X; Yang G; Min X; Deng M
    Biocell; 2011 Dec; 35(3):71-9. PubMed ID: 22423483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dietary flavones apigenin and luteolin impair smooth muscle cell migration and VEGF expression through inhibition of PDGFR-beta phosphorylation.
    Lamy S; Bédard V; Labbé D; Sartelet H; Barthomeuf C; Gingras D; Béliveau R
    Cancer Prev Res (Phila); 2008 Nov; 1(6):452-9. PubMed ID: 19138992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adiponectin inhibits insulin-like growth factor-1-induced cell migration by the suppression of extracellular signal-regulated kinase 1/2 activation, but not Akt in vascular smooth muscle cells.
    Motobayashi Y; Izawa-Ishizawa Y; Ishizawa K; Orino S; Yamaguchi K; Kawazoe K; Hamano S; Tsuchiya K; Tomita S; Tamaki T
    Hypertens Res; 2009 Mar; 32(3):188-93. PubMed ID: 19262481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional regulation of VCAM-1 expression by tumor necrosis factor-alpha in human tracheal smooth muscle cells: involvement of MAPKs, NF-kappaB, p300, and histone acetylation.
    Lee CW; Lin WN; Lin CC; Luo SF; Wang JS; Pouyssegur J; Yang CM
    J Cell Physiol; 2006 Apr; 207(1):174-86. PubMed ID: 16288471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ablation of MEK kinase 1 suppresses intimal hyperplasia by impairing smooth muscle cell migration and urokinase plasminogen activator expression in a mouse blood-flow cessation model.
    Li Y; Minamino T; Tsukamoto O; Yujiri T; Shintani Y; Okada K; Nagamachi Y; Fujita M; Hirata A; Sanada S; Asanuma H; Takashima S; Hori M; Johnson GL; Kitakaze M
    Circulation; 2005 Apr; 111(13):1672-8. PubMed ID: 15795331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells.
    Lee WJ; Chen WK; Wang CJ; Lin WL; Tseng TH
    Toxicol Appl Pharmacol; 2008 Jan; 226(2):178-91. PubMed ID: 17961621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of ERK1/2 and p38(MAPK) by components of the Rho signaling pathway during sphingosine-1-phosphate-induced smooth muscle cell migration.
    Galaria II; Fegley AJ; Nicholl SM; Roztocil E; Davies MG
    J Surg Res; 2004 Dec; 122(2):173-9. PubMed ID: 15555614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-1beta induces MMP-9 expression via p42/p44 MAPK, p38 MAPK, JNK, and nuclear factor-kappaB signaling pathways in human tracheal smooth muscle cells.
    Liang KC; Lee CW; Lin WN; Lin CC; Wu CB; Luo SF; Yang CM
    J Cell Physiol; 2007 Jun; 211(3):759-70. PubMed ID: 17311279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase.
    Hu XW; Meng D; Fang J
    Carcinogenesis; 2008 Dec; 29(12):2369-76. PubMed ID: 18974065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of MAPKs and NF-kappaB in LPS-induced VCAM-1 expression in human tracheal smooth muscle cells.
    Lin WN; Luo SF; Lee CW; Wang CC; Wang JS; Yang CM
    Cell Signal; 2007 Jun; 19(6):1258-67. PubMed ID: 17303384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative regulation of MEKK1/2 signaling by serine-threonine kinase 38 (STK38).
    Enomoto A; Kido N; Ito M; Morita A; Matsumoto Y; Takamatsu N; Hosoi Y; Miyagawa K
    Oncogene; 2008 Mar; 27(13):1930-8. PubMed ID: 17906693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MLCK-independent phosphorylation of MLC20 and its regulation by MAP kinase pathway in human bladder smooth muscle cells.
    Deng M; Ding W; Min X; Xia Y
    Cytoskeleton (Hoboken); 2011 Mar; 68(3):139-49. PubMed ID: 20722044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells.
    Rousseau S; Houle F; Landry J; Huot J
    Oncogene; 1997 Oct; 15(18):2169-77. PubMed ID: 9393975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1.
    Widmann C; Johnson NL; Gardner AM; Smith RJ; Johnson GL
    Oncogene; 1997 Nov; 15(20):2439-47. PubMed ID: 9395240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Src and Cas are essentially but differentially involved in angiotensin II-stimulated migration of vascular smooth muscle cells via extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase activation.
    Kyaw M; Yoshizumi M; Tsuchiya K; Kagami S; Izawa Y; Fujita Y; Ali N; Kanematsu Y; Toida K; Ishimura K; Tamaki T
    Mol Pharmacol; 2004 Apr; 65(4):832-41. PubMed ID: 15044612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apigenin inhibits immunostimulatory function of dendritic cells: Implication of immunotherapeutic adjuvant.
    Yoon MS; Lee JS; Choi BM; Jeong YI; Lee CM; Park JH; Moon Y; Sung SC; Lee SK; Chang YH; Chung HY; Park YM
    Mol Pharmacol; 2006 Sep; 70(3):1033-44. PubMed ID: 16782805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unbalanced activation of ERK1/2 and MEK1/2 in apigenin-induced HeLa cell death.
    Llorens F; Miró FA; Casañas A; Roher N; Garcia L; Plana M; Gómez N; Itarte E
    Exp Cell Res; 2004 Sep; 299(1):15-26. PubMed ID: 15302569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone inhibits homocysteine-induced migration of vascular smooth muscle cells through a peroxisome proliferator-activated receptor gamma-independent mechanism.
    Li L; Gao PJ; Xi R; Wu CF; Zhu DL; Yan J; Lu GP
    Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1471-6. PubMed ID: 18759864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways.
    Jang SI; Kim HJ; Kim YJ; Jeong SI; You YO
    Eur J Pharmacol; 2006 Aug; 542(1-3):1-7. PubMed ID: 16797002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder.
    Morelli A; Vignozzi L; Filippi S; Vannelli GB; Ambrosini S; Mancina R; Crescioli C; Donati S; Fibbi B; Colli E; Adorini L; Maggi M
    Prostate; 2007 Feb; 67(3):234-47. PubMed ID: 17163492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.